Pelthos Therapeutics Inc.
PTHS NYSE
SEC CIK 1919246
Follow Pelthos Therapeutics
Weekly email: filings, results
Revenue, last quarter
$15.4M
+107.9% vs same quarter last year
Net income
−$7.9M
+51.4% vs same quarter last year
EPS, diluted
−$2.04
+61.5% vs same quarter last year
Operating cash flow
−$5.2M
+66.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$43.3M |
| FY24 | −$8M |
| FY23 | −$7.4M |
| FY22 | - |
| FY21 | - |